drug
riociguat
Marketedupdated 6mo agoby Bayer HealthCare Pharmaceuticals Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying riociguat
- phase4Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
- phase3Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
- phase2Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty
- phase2Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
- phase3Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH
- phase4A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
- phase2A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
- phase2Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 4, 2026
14 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (20)
- Feb 18, 2034compositionUS 10662188
- Feb 18, 2034compositionUS 10662188
- Feb 18, 2034compositionUS 10662188
- Feb 18, 2034compositionUS 10662188
- Feb 18, 2034compositionUS 10662188
- Feb 18, 2034compositionUS 11203593
- Feb 18, 2034compositionUS 11203593
- Feb 18, 2034compositionUS 11203593
- Feb 18, 2034compositionUS 11203593
- Feb 18, 2034compositionUS 11203593
- Feb 18, 2034formulationUS 12503469
- Feb 18, 2034formulationUS 12503469
- Feb 18, 2034formulationUS 12503469
- Feb 18, 2034formulationUS 12503469
- Feb 18, 2034formulationUS 12503469
- Dec 4, 2026compositionUS 717303714d
- Dec 4, 2026compositionUS 717303714d
- Dec 4, 2026compositionUS 717303714d
- Dec 4, 2026compositionUS 717303714d
- Dec 4, 2026compositionUS 717303714d
News(1)
- Merck outlines 2027 as ‘another year of investment’ despite recent clinical winsEven as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial expansions over near-term margin growth, hoping to strengthen its long-term…fiercebiotech · 21d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that